罗沙司他与重组人促红细胞生成素治疗维持性血液透析肾性贫血的临床效果比较
Clinical effects of roxadustat versus recombinant human erythropoietin in treatment of maintenance hemodialysis patients with renal anemia
刘鹏程1
作者信息
- 1. 扬州大学附属苏北人民医院,江苏扬州,225009
- 折叠
摘要
目的 比较罗沙司他与重组人促红素(rHuEPO)在维持性血液透析肾性贫血患者中的疗效.方法 从2021年1月—2023年12月扬州大学附属苏北人民医院收治的维持性血液透析肾性贫血患者中选取100例作为研究对象,依据治疗手段的不同,分为对照组和观察组,每组50例.2组均接受补铁治疗,对照组使用rHuEPO,观察组使用罗沙司他.对2组的贫血指标和铁代谢指标及不良反应发生情况进行观察与比较.结果 在接受治疗之前,2组患者指标比较,差异无统计学意义(P＞0.05).接受治疗后,2组患者的指标比治疗前有所提升,而且观察组均高于对照组,差异有统计学意义(P＜0.05).观察组不良反应发生率为2.00％,低于对照组的16.00％,差异有统计学意义(P＜0.05).结论 与rHuEPO相比较,罗沙司他能够显著改善贫血和铁代谢状况,使用安全性和应用价值均很高.
Abstract
Objective To compare the clinical effects of roxadustat and recombinant human erythropoietin(rHuEPO)in treatment of maintenance hemodialysis patients with renal anemia.Meth-ods From January 2021 to December 2023,100 patients with renal anemia undergoing maintenance hemodialysis admitted to Northern Jiangsu People's Hospital Affiliated to Yangzhou University were se-lected as study subjects.Based on different treatment approaches,they were divided into control group(n=50)and observation group(n=50).Both groups received iron supplementation therapy,with the control group using recombinant human erythropoietin(rHuEPO)and the observation group using roxa-dustat.Anemia indicators,iron metabolism indicators,and the incidence of adverse reactions were ob-served and compared between the two groups.Results Before treatment,there was no statistically sig-nificant difference in the indicators between the two groups(P＞0.05).After treatment,the indicators of both groups improved compared to before treatment,and the indicators of the observation group were superior to those of the control group(P＜0.05).The incidence of adverse reactions in the observation group was 2.00％,which was lower than 16.00％in the control group(P＜0.05).Conclusion Com-pared with rHuEPO,roxadustat can significantly improve anemia and iron metabolism,with high safety and application value.
关键词
罗沙司他/重组人促红细胞生成素/维持性血液透析/肾性贫血/铁代谢/不良反应Key words
roxadustat/recombinant human erythropoietin/maintenance hemodialysis/renal anemia/iron metabolism/adverse reactions引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据